Sporadic synchronous colorectal cancer (CRC) refers to more than one primary tumor detected in a single patient at the time of the first diagnosis without predisposition of cancer development. Given the same genetic and microenvironment they raise, sporadic synchronous CRC is a unique model to study CRC tumorigenesis. We performed whole exome sequencing in 32 fresh frozen tumor lesions from 15 patients with sporadic synchronous CRC to compare their genetic alterations. This approach identified ubiquitously mutated genes in the range from 0.34% to 4.22% and from 0.8% to 7.0% in non-hypermutated tumors and hypermutated tumors, respectively, in a single patient. We show that both ubiquitously mutated genes and candidate cancer genes from different tumors in the same patient mutated at different sites. Consistently, obvious differences in somatic copy number variations (SCNV) were found in most patients with non-hypermutated tumor lesions, which had ubiquitous copy number amplification rates ranging from 0% to 8.8% and ubiquitous copy number deletion rates ranging from 0% to 8.2%. Hypermutated lesions were nearly diploid with 0% to 18.8% common copy number aberrations. Accordingly, clonal structures, altered signaling pathways and druggable genes in a single patient with synchronous CRC varied significantly. Taken together, the disparate SCNVs and mutations in synchronous CRC supported the field effect theory of tumorigenesis. Moreover, the intertumor heterogeneity of synchronous CRCs implies that analysis of all tumor lesions from the same patient is necessary for appropriate clinical treatment decisions.
with predisposing conditions such as adenoma, inflammatory bowel diseases (IBDs), hereditary nonpolypsis CRC and familial adenomatous polyposis (FAP). [3] [4] [5] [6] Sporadic synchronous CRC refers to synchronous CRC without predisposition of cancer development. Sporadic synchronous tumors arise in a common genetic and environmental background, which can provide a unique model to study CRC tumorigenesis.
Two hypotheses have been proposed to explain the occurrence of these physically separated independent tumors. The clonal hypothesis suggested that multifocal tumors arose from the same origin, a founder tumor, and the other tumors were formed by intraluminal or intraepithelial seeding of cells from the founder tumor. In contrast, the field hypothesis emphasized the significance of tumor microenvironment in multiple tumorigenesis. It is believed that a carcinogen may partially transform a large area of cells and then induce neoplastic transformation by subsequently acquired additional mutations. Accordingly, each hypothesis would generate a different genetic signature, since cancer occurs by the sequential accumulation of transformative mutations. 7 Comparative analyses of synchronous CRCs have focused mostly on the status of microsatellites, on mismatch-repair proteins and on mutation hotspots in known cancer genes. These studies report both concordant and discordant alterations between synchronous tumors. [8] [9] [10] [11] [12] For example, a previous study suggested that synchronous CRCs with discordant p53 and KRAS mutations may represent independently developing tumor foci. 12 However, another group examined global DNA methylations within synchronous CRC pairs and observed concordant patterns of epigenomic and epigenetic events, which indicated that synchronous CRC pairs exhibited strong correlation. 1 As cancer is genetically unstable, investigating the relationship between paired tumors merely by selected mutational markers could drastically change their predicted molecular origins. Therefore, we hypothesized that a better approach to study the genetic origin of synchronous CRC is through the thousands of unbiased genetic markers generated by next-generation sequencing. In our study, to investigate the development of sporadic synchronous CRC pairs, we performed whole exome sequencing (WES) in 32 fresh frozen tumor lesions from 15 patients. Excluding synchronous CRC patients with predisposition of cancer development, such as Lynch syndrome, IBD and FAP, may reduce the interference by congenital deficiencies. We analyzed somatic mutations, copy number alterations, clonal structures and affected signaling pathways. In addition to the apparent intertumor heterogeneity, our results indicated distinct genetic origins of synchronous CRCs.
Material and Methods

Tumor specimen
For the use of these clinical samples for research, we obtained prior written informed consent of the patients and approval from the Research Ethics Committee of Peking University Cancer Hospital and Institute, Beijing, China (No. 2014KT98). Our study involved 15 patients diagnosed with synchronous CRC, who received tumor resection at the Department of Gastrointestinal Surgery IV, Peking University Cancer Hospital and Institute. All the surgically removed tumor tissues were freshly frozen. All the tumor tissues were stained with hematoxylin and eosin, and tumor cell population was confirmed to be >70% by two pathologists. For each synchronous tumor pair, a matched blood sample or normal peritumoral tissue was taken as reference.
DNA extraction and library preparation
Genomic DNA from tumor pairs and reference samples was extracted using QIAamp DNA Mini Kit (Qiagen, Dusseldorf, Germany) following the manufacturer's instructions. Following this, the total DNA was used to generate genomic DNA libraries according to the protocols provided by Illumina. A custom targeted capture kit that covered all exons, amounting to 50 Mb, was designed using the Agilent SureSelect Human All Exon V5 Kit (Agilent Technologies, Santa Clara, CA).
Whole exome sequencing
Exome-capture sequencing was performed with genomic DNA from tumor and matched normal samples. The amplified normal and tumor DNA libraries were sequenced with the Illumina HiSeq Xten Genome Analyzer (Illumina, San Diego, CA), yielding 150 bp of paired end sequence, and FASTQ files were generated.
Reads alignment
All normal and tumor-sequenced reads were then aligned to the reference human genome (GRCh37) using BurrowsWheeler Aligner (BWA, version 0.7.10), and subsequently realigned by the Genome Analysis Toolkit (GATK, version 2.3.1) to correct the mismatch due to the presence of local insertions or deletions in individual genomes with respect to What's new? In synchronous colorectal cancer (CRC), more than one primary colorectal tumor is detected at diagnosis. Whether such synchronous tumors from a single patient have similar genetic profiles is unknown. Here, using whole genome sequencing, the authors show that somatic mutations, patterns of somatic copy number alteration, clonal structures, affected signaling pathways and druggable genes in synchronous CRCs from a single patient vary significantly. The results reveal vast intertumor heterogeneity in synchronous CRC, wherein primary tumors have distinct genetic origins, and support the field effect theory of tumorigenesis, with tumors exhibiting different genetic signatures induced by independent cancer-initiating events.
the reference genome. After realignment, Picard (version 1.103) was used to mark duplicate reads and GATK to generate base recalibration table to compensate for systematic errors. The final BAM files were used as input files for variants calling.
Somatic variant calling and filtering
Variant calling was carried out by a series of published software according to their instructions. We applied MuTect (version 1.1.6) for somatic nucleotide variation (SNV) calls and Strelka (version 1.0.14) for INDEL calls by comparing the sequencing reads of the tumor and matched normal genomes. We then applied vcf2maf to annotate all the somatic variants, with online databases such as the Catalogue of Somatic Mutations in Cancer (COSMIC) and the Single Nucleotide Polymorphism database (dbSNP138). All the variants in coding regions were visually inspected using Integrative Genomics Viewer (IGV, version 2.3.34) for validation. Filtered mutations which identified as PASS by MuTect were analyzed using MutsigCV1.4 software, by which candidate cancer driver genes were enriched (p < 0.05). Polymerase chain reaction (PCR) and Sanger sequencing were performed for all frequently mutated genes to validate WES and to evaluate the accuracy of calls.
Mutation validation by PCR-based Sanger sequencing
A touch-down PCR (Td-PCR) approach was used to amplify targeting mutation sites in genomic DNA samples. Each Td-PCR was performed in volumes of 25 lL containing 2.5 lL of 10X assay buffer, 2.5 mM dNTP mix, 1 ng of primer, 2.5 unit of Taq DNA polymerase and 20 ng of template DNA (all PCR reagents were purchased from ThermoFisher Scientific, Waltham, MA). Td-PCRs were carried out in a Veriti Thermal Cycler (ThermoFisher Scientific, Waltham, MA) with the following amplification profiles: the initial denaturation step with Taq DNA polymerase was 5 min at 948C, followed by a 30-cycle PCR consisting of 20 sec at 948C for denaturation, 20 sec at 658C to 508C for annealing and 50 sec at 728C for elongation. The annealing temperature was reduced by 0.58C per cycle for the first 30 cycles (touchdown cycles). Amplification of the targeted DNA templates continued for further 10 cycles consisting of 20 sec at 948C for denaturation, 20 sec at 508C for annealing and 50 sec at 728C for elongation. The reactions were ended with a final extension step at 728C for 5 min. Subsequently, the PCR products were separated on 1.5% agarose gel. The targeting fragments were purified with SanPrep Column DNA Gel Extraction Kit (Sangon Biotech, Shanghai, China) according to the manufacturer's instructions and then sent to Sanger sequencing.
Copy number profiling
Purity analysis of tumor was carried out by sequenza 2.1.2 software. 13 Copy number was inferred from sequencing data in all 32 tumor samples using the software package CNVkit-
14 CNVkit is a Python library and command-line software toolkit to infer and visualize copy number from targeted DNA sequencing data. It calculated the log2ratio of each segment and inferred the copy number according to purity values calculated by sequenza (http://cnvkit.readthedocs.io/en/ stable/index.html).
Clonal structure construction
After copy number and tumor purity were assessed, we used sequenza2PyClone module to generate pyclone input files. Then we filtered the input files based on the MuTect results. Shared mutations in different tumor samples were calculated using PyClone 0.13.1 to infer clonal population structures in cancers. 15 
Gene ontology enrichment analysis for all mutations
Significance of each gene ontology (GO) term was calculated by hypergeometric distribution test for a number of different genes in each GO term. The calculation returns p values for significance of enrichment. Terms with low p values represent significantly enriched entries. The formula of enrichment score is as follows:
In the formula, N represents the number of genes in all terms that have GO annotations; n represents the number of mutant genes that have GO annotations; M represents the number of genes that have annotations in specific GO term; m represents the number of mutant genes which have annotations in specific GO terms. Subsequently, GO terms of each category (molecular function, biological process and cellular component) with more than five mutated genes and p < 0.05 were selected.
Drug-Gene Interaction Database screening
The Drug Gene Interaction Database (http://dgidb.genome. wustl.edu/) was used to predict actionable and druggable mutated genes. 16 
Results
Genomic landscape of 15 patients with synchronous CRC
In total, 47 fresh frozen samples from 15 patients with sporadic synchronous CRCs were submitted to WES, including 32 cancer foci and 15 matched blood or non-cancerous colorectal tissue samples as germline comparators (Supporting Information Table S1 ). All samples were obtained by surgical resection from patients without pre-operative chemo-or radiotherapy. The clinicalpathological characteristics of all patients are shown in Supporting Information Table S1 . We obtained an average target depth of 208x per sample after removing duplicates by uniquely mapping 150 bp reads from paired-end sequencing (Supporting Information Table  S2 ). We termed it as a mutation being present in a tumor if a nucleotide substitution occurred in at least 10% reads in at least one tumor lesion. The somatic mutation rate varied considerably among the samples. We separated the samples into two groups, hypermutated samples (n 5 5) that had mutation rates of 1.9 to 7.5 per 10 6 (median number of total mutations, 1528) and non-hypermutated samples (81.8%, n 5 27) with mutation rates of 0.1 to 0.7 per 10 6 (median number of total mutations, 116). In total, three patients (Patients 230, 338 and 384) had hypermutated tumors. According to the pathological reports and mutation information, Patient 230 expressed high levels of MLH1 and PMS2, expressed MSH6 in a few cells and lacked MSH2. Patient 338 expressed MLH1, MSH2 and MSH6 in >75% of the tumor, whereas Patient 384 showed high MLH1 expression but lacked MSH2 and MSH6. Tumors 230-1 and 338-2 were hypermutated probably also due to MSH3 missense mutation-induced mismatch repair deficiency. MSH2 and MSH6 were mutated in Tumor 230-2, which might be the reason for its extraordinarily high number of mutations. 17, 18 None of the other mismatch repair-related genes were found mutated in tumor samples in Patient 384.
In patients with non-hypermutated tumors, we identified 2733 non-synonymous and 874 synonymous somatic single nucleotide variations (SNVs) and 154 INDELs. The mutations observed in non-hypermutated CRC cases are listed with detailed information of locations and functional consequences in Supporting Information Table S3 . Moreover, in patients with hypermutated tumors, we observed 7323 nonsynonymous mutations, 2515 synonymous mutations and 408 INDELS (Supporting Information Table S3 ). Figures 1a  and 1b show the number of different mutation types in each tumor. A random selection of these mutant genes was validated independently with Sanger sequencing, and the average validation rate was found to be 95.1%. Primer sequences used for PCR-based Sanger sequencing are listed in Supporting Information Table S4 .
It is well established that most somatic SNVs acquired in CRC are C > T transitions. 19 Consistently, we observed that C > T transitions were the most common type of event in 14 of 15 patients, accounting for 54.25% of all detected mutations. Higher frequencies of transition mutations at CpG dinucleotides in CRC may result from high DNA methylation levels. 19, 20 Only Patient 335 had a higher C > A than C > T transition (Fig. 1c) .
We then determined significantly mutated genes (SMGs) in the non-hypermutated tumors by the MuSiC pipeline. SMGs are those genes that show a significantly higher mutation rate than the background mutation rate when multiple mutational mechanisms such as coding INDEL, single nucleotide substitution and splice site mutation are taken into account. 21 We KRAS, FBXW7, OR4C5, OR51B6, SENP7, TNKS and LRP1B. The roles of OR4C5, OR51B6, SENP7 and LRP1B in CRC have not been well studied. SENP7 is involved in neuronal differentiation, 22 DNA repair 23 and meiosis. 24 OR51B6 might play a regulatory role in gamma-globin gene expression.
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LRP1B may function as a tumor suppressor that regulates cell motility via RhoA/Cdc42 pathway and actin cytoskeleton reorganization in renal cell cancer. 26 The function of OR4C5 is currently unknown. Interestingly, a few frequently mutated genes such as SMAD4, PIK3CA and NRAS, in sporadic CRC, which are often found in solitary CRC, 18 were rarely mutated in synchronous lesions.
Mutation analysis revealed intertumor heterogeneity of synchronous tumors
We then analyzed the focal distribution of non-synonymous mutations in patients with non-hypermutated tumors. WES identified on average 102 (ranging from 39 to 233) nonsynonymous mutations per sample, and we observed that mutations in different tumor foci in the same patient varied significantly (Fig. 2a) . Ubiquitously mutated genes were defined as mutated genes present in all lesions in a single patient. Very few ubiquitously mutated genes were identified, ranging from 0.34% to 4.22% among different patients, indicating intertumor heterogeneity in synchronous lesions. Moreover, ubiquitously mutated genes in the same patient were mutated at different loci (Supporting Information Table S5 ). For patients with hypermutated tumors, WES determined, on average, 1,232 non-synonymous mutations. As shown in Figure 2b , the proportions of ubiquitously mutated genes in patients with two hypermutated tumors were higher, at 7.0% and 5.4% for Patient 230 and 384, respectively. Patient 338 had a hypermutated tumor and a non-hypermutated tumor, and the ubiquitously mutated genes were 0.8%. Although patients with hypermutated tumors had more mutated ubiquitous genes, none of those genes mutated at the same site (Supporting Information Table S6 ). Sanger sequencing confirmed that ubiquitously mutated genes altered at different locations. These results show intertumor mutational heterogeneity of synchronous lesions. These data also suggest that sequencing only a single lesion cannot completely characterize the genomic landscape of multiple CRC lesions in most patients. To determine whether different tumor loci in the same patient have similar cancer gene mutations, we mapped candidate cancer genes from the Catalogue of Somatic Mutations in Cancer (COSMIC) Cancer Gene Census list and driver genes reported in literature. 18, 21, [27] [28] [29] In total, 122 mutated cancer genes were matched. Figure 3 shows the top 50 mutated cancer genes. Mutations in the cancer genes-APC, TP53 and KRAS were the most prevalent drivers, consistent with their crucial roles in CRC development. 27 Furthermore, we analyzed the distribution of mutation sites in ubiquitously mutated cancer genes in tumor lesions from the same patient. The mutations of KRAS gene usually occur on codon 12. However, we found that the KRAS gene only in Patient 335 had exactly the same mutation sites, whereas the rest of those shared mutated genes alternate at different sites in different foci of the same patient, as shown in Supporting Information Table S5 . Given the high frequency of KRAS mutation in CRC and that the remaining genetic alterations were entirely different, this suggested that the sharing of the KRAS mutation in Patient 335 was likely a random event.
The ubiquitous cancer gene mutation loci were also confirmed by Sanger sequencing (Supporting Information Fig.  S1 ). Taken together, these results indicate that synchronous lesions were initiated by different driver genes and subsequently acquired lesion-specific somatic mutations during tumor development.
Somatic copy number variations also demonstrated distinct genetic origins of synchronous CRCs
To define the role of chromosomal aberrations in synchronous CRCs, we assessed somatic copy number variations (SCNVs). Copy number gains and losses were found in The colors in the heatmaps represent copy number gain (red) and loss (blue). A gain was defined as a copy number at least one greater than ploidy, whereas a loss was defined as a copy number at least one less than ploidy.
nearly all lesions of 15 patients, implying their important roles in tumorigenesis. Segmented copy number calls derived from CNVkit are included in Supporting Information Table  S7 . In non-hypermutated tumors, SCNV analysis revealed extensively heterogeneous profiles within patients and most samples were aneuploid with frequent chromosome gains or losses (Fig. 4a) . Lesions from the same patient did not share the majority of the chromosomal aberrations (Fig. 5) , indicating substantial intertumor chromosomal heterogeneity. As shown in Figures 4a and 5 a, obvious differences in CNV were found in most patients with non-hypermutated tumor lesions, which had ubiquitous copy number amplification rates ranging from 0% to 8.8% and ubiquitous copy number deletion rates ranging from 0% to 8.2%, consistent with the intertumor heterogeneity in mutations. In contrast, hypermutated lesions were nearly diploid (Fig. 4b) . These results are inconsistent with previous reports. 30 As shown in Figure 5b , copy number gains and losses were much less in Patients 230, 338 and 384. However, 338-1 was a non-hypermutated lesion with more CNVs. The percentage of ubiquitous recurrent CNVs varied from 0% to 18.8% across different patients with hypermutated tumors.
Further analysis showed that 21p11.2-21p11.1, 20q11.21-20q13.33 and 1q21.3 were most frequently amplified, as observed in 37.5% (12 of 32), 23.1% (6 of 26) and 23.1% (6 of 26) of the non-hypermutated tumors, respectively. Gain in 20q has been frequently found in CRCs and is important in adenoma-carcinoma transformation. 31 In addition, amplification in 20q is associated with poor prognosis in CRC. 32 Gain in 1q21.3 is also common in CRC. 1q21.3 harbors S100A2 which is a calcium-binding protein that promotes p53 function. 33 However, amplification of 21p has not been reported in CRC. 21p contains TPTE whose expression was upregulated in liver, prostate, and lung cancer. [34] [35] [36] Copies of the TPTE gene are located on chromosomes 13, 15, 21, 22 and Y, but only the copy on chromosome 21 seems to be expressed. 37 Interestingly, we observed copy number gains in 21p11.2-21p11.1 in all the patients with hypermutated tumors. Xp22.33-Xp11.1 and 18p11.21-18p11.1 were most frequently deleted, as observed in 37.5% (12 of 32) and 35% (8 of 32) of the non-hypermutated tumors, respectively. Gain of chromosome X was common in CRC, 33 whereas loss of Xp was not. Frequent copy number loss in 18p, which occurs in 20.7% of CRCs, has been reported. However, no correlation was found between 18p loss and patient survival. 38 CNV events are considered to occur early during tumorigenesis, as reported in other cancer types and CRC. [39] [40] [41] The disparate SCNV patterns suggested that multiple lesions from the same patient may have originated from different ancestors and developed independently.
Synchronous CRCs exhibit different clonal structures
Tumors often consist of multiple genotypically distinct cell populations, referred to as clones. These clones are related through a phylogeny. During tumor progression they undergo selections in tumor microenvironments and drug interventions. To address whether the tumorigenesis of different CRC tumors in one individual requires the acquisition of the same genetic events, or whether they were driven by distinct factors, we then compared the clone components of different tumors in the same patient by PyClone. Pyclone grouped sets of deeply sequenced somatic mutations into putative clonal clusters while estimating their cellular prevalence and accounting for allelic imbalances introduced by SCNVs and normal cell contamination. 15 As shown in Figure  6 , our results hinted at multiclonality in CRC. The probability density of the clusters indicated the cellular prevalence of mutations; in other word, the proportion of corresponding subclone cells in each sample. Larger width means higher probability of the cellular prevalence in certain proportion, and broader range in the scatter indicates that there is uncertainty in the cellular prevalence of the mutations. Nevertheless, clusters with one mutation will typically have more uncertainties than those with multiple mutations. Different clone structures of tumors in the same patient indicate that their genetic determinants of the phenotype vary; different tumors have their own growth and proliferative capability. Accordingly, they may have different metastatic potential or chemotherapeutic resistance. It is of great interest that tumors from the same patients in the same tumor microenvironment without drug usage contain different clones.
Altered pathways in synchronous CRC
The intertumor genomic diversity of synchronous CRC was evident in all tested patients. Evolving intertumor genomic heterogeneity in CRC reveals a complex divergence of misregulation of cancer-cell signaling pathways and intertumor mutational heterogeneity may shed light on personalized therapy. Most mutated genes do express and give rise to abnormal proteins affecting different cancer signaling pathways. Therefore, we made functional predictions of the nonsynonymous mutations in different tumor foci. The top five GO terms based on biological processes, cellular component and molecular function showed that the mutated genes in 5 of 15 patients had completely different altered pathways, whereas the altered genes in others clustered in at a maximum of three similar terms (Supporting Information Fig. S2 ). The top three affected biological processes included positive and negative regulation of transcription from RNA polymerase II promoter and cell adhesion. The top three affected cellular components were plasma membrane, cytoplasm and integral component of plasma membrane. The top three altered molecular functions included calcium ion binding, ATP binding and zinc ion binding. Supporting Information Table S8 shows the top five affected terms (if there were) with more than five enriched genes and a p values lower than 0.05 in each category. Functional heterogeneity in different lesions from the same patient suggested different regulatory signaling and cellular metabolic pathways, which indicates the necessity of target medicine.
Clinical implications of intertumor heterogeneity of synchronous CRC
To determine the clinical effect of intertumor heterogeneity of synchronous CRC, we predicted actionable and druggable gene mutations using the well-established Drug-Gene Interaction Database. Drugs in this database are used clinically or are currently in clinical trials. The results show that the patterns of potentially druggable mutated genes are heterogeneous in different foci from the same patient. All patients had few common druggable genes (Supporting Information  Table S9 ), and tumors from each patient show a divergent complexity of additional actionable and druggable mutated genes, as well as potential drug resistant genes. Common druggable genes with different mutation loci make it more complex to choose effective drugs. These results indicate that it is of great importance to examine specimens from all tumors in the same patient to make appropriate treatment decisions.
Discussion
In our study, integrated analysis of somatic mutations, copy number aberrations and some well-defined pathways showed that the tumorigenic genomic events that occurred in different tumors within one individual were disparate, suggesting sporadic synchronous CRC has different genetic origins, and the divergent complexity of mutations may inevitably change the biological functionalities that are linked to intertumor heterogeneity.
We observed few shared SCNVs and SNVs in cancer genes as well as other genes between different foci in patients with synchronous CRC. SCNVs often lead to gene dosage effects that promote tumor growth through the overexpression of oncogenes or downregulation of tumor suppression genes. 42 Our results indicated that the majority of copy number aberrations at the earliest stages during tumor evolution acquired by the tumor lesions from the same patients were different. 42 Mutations are defined as "early" if they occur in a large cancer cell fraction and the mutation copy number is high. Ubiquitous mutations also represent relatively early events during tumorigenesis, since they occurred before the most recent clonal expansion. 43 Mutations in cancer driving genes-APC, TP53 and KRAS, for example, are demonstrated to drive colorectal tumorigenesis by modulating driver pathways that are involved in proliferation, differentiation and apoptosis to acquire selective growth advantages to mutated cells. 44 According to our data, not only a few ubiquitously mutated genes were found in synchronous CRC but ubiquitously mutated genes and cancer genes in synchronous CRC mutated at different sites, indicating that the timing at which they accumulated were different. Consequently, the clonal structures of the tumors from the same patient were different, and the number of driver pathway alterations in synchronous CRC is highly variable. These strongly indicate that sporadic synchronous CRCs are of different genetic origins. This finding has important implications for the development of genetic prognostic and predictive biomarkers: (i) for diagnosis, multiple biopsies should be examined since single biopsy might miss genetically distinct tumor lesions leading to misclassification of CRC; (ii) the manner in which specific individual malignant clones contribute to disease progression must be clarified.
Our results suggest an environmental field effect that promotes multiple colorectal tumors, in agreement with previous studies in other types of synchronous tumors, including bilateral renal cell carcinomas 45 and thyroid carcinoma. 46 The molecular basis for this phenomenon could be massive exposure to a carcinogen or a genetic predisposition for cancer development in a patient. As a potential mechanism of field effect, Cereda et al. showed that the frequency of independent cancer-initiating events could be increased due to inherited damaging alterations of immune-related genes, implying that the inflammatory microenvironment favors tumorigenesis via increased genomic instability or via cytokine and growth factor secretion. 47, 48 Epigenetic alterations have also been proposed as a mechanism of field effect. Low LINE-1 methylation level is associated with poor prognosis of patients with colon cancer. 49 It has been reported that LINE-1 methylation level is lower in some colon cancers and adjacent normal colon mucosa than peripheral blood from the same patients or normal colon mucosa in healthy individuals. 50 Moreover, some sporadic synchronous CRCs may arise from a field defect caused by the epigenetically inactivated MGMT promoter and increased mutation rate in multiple genes, including KRAS. 51 The heterogeneity of synchronous tumors may affect the efficiency of gene targeting therapies and may interfere with optimal treatment with current therapies or newer targeted agents. Our results show that the heterogeneity of synchronous CRCs affects not only a few common druggable genes but also additional actionable and druggable mutated genes, as well as potential drug resistant genes. Previous studies showed that different genotypes of druggable genes KRAS, NRAS, PIK3CA and BRAF in synchronous CRCs were different. 9 Testing for RAS mutations in only one of the primary lesions in synchronous CRC can misguide clinical decisions and influence the predictive potential of anti-EGFR treatment. 10 Moreover, a divergent complexity of additional actionable genes may increase the chance of drug resistance.
Therefore, for precise medicine, it is of great importance to analyze all the lesions within one individual to make effective treatment decisions.
In conclusion, our analysis of 15 patients with sporadic synchronous CRCs indicate that synchronous tumors in the same patient were of different genetic origins, which were initiated by different driver genes and acquired different somatic mutations during tumor progression. The disparate SCNVs and mutations in tumor lesions from the same patients supported the field effect theory of synchronous tumorigenesis. Moreover, the intertumor heterogeneity of synchronous CRCs implies that analysis of all tumor lesions from the same patient is necessary for appropriate clinical treatment.
